Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China

• DOI: 10.5582/ddt.2022.01024
• Publication Date: 2022-04-19T22:11:24Z
• Authors: Peize Zhang; Jie Tan; Yi Lin; Hailin Zhang; Guofang Deng; Xiaoyou Chen
• Keywords: 0301 basic medicine; China; 03 medical and health sciences; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Multidrug-Resistant; Antitubercular Agents; Linezolid; Humans; Mycobacterium tuberculosis; 3. Good health

Linezolid has been one of the key anti-tuberculosis agents for the treatment of multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). It used to be very expensive and was not covered by social insurance from local governments. Nevertheless, a growing number of patients in China received linezolid in their anti- MDR/XDR TB regimens over the past decade. Many scholars in China have reported their experience using linezolid to treat patients with MDR/XDR-TB. In view of this, existing evidence of the efficacy and safety of linezolid and problems faced by Chinese patients with MDR/XDR-TB are summarized here.